Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vosoritide in infants and young children with achondroplasia
NCT03583697Phase 2Completed
- Sponsor
- BioMarin Pharmaceutical
- Start
- Jun 2018
- Primary completion
- Jan 2022
- Modality
- Peptides
- Countries
- 4
01
Overview
A Phase 2 trial of vosoritide in achondroplasia (ACH), sponsored by BioMarin Pharmaceutical. Started Jun 2018; status: completed.
02
Drugs
vosoritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT03583697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03583697.